- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07719127
Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High Grade Glioma
A Window-of-Opportunity Study of Disulfiram to Reduce Myeloid Immunosuppression and Steroid Dependence in Resectable High-Grade Glioma
This research study is for participants with glioblastoma. It can cause a tumor immunosuppression which helps myeloid cells that can stop T-cell function. Disulfiram is a drug that has been used in treating other disorders, but this study will examine if disulfiram can help make the tumor environment less immunosuppressive and reduce brain swelling when taken before surgery.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Descrição detalhada
Glioblastoma is one of the most common brain cancers that affect adults and is very hard to treat. This is due to myeloid cells, which are special immune cells in the body that prevent the body from recognizing and attacking the tumor. Because of this, immunotherapies have not worked well in treating glioblastoma.
Disulfiram may also reduce brain swelling, which may decrease or delay the need for subjects to be treated with steroids.
The purpose of this study is to find out if disulfiram can help reduce immunosuppression and help prevent edema symptoms when taken 3-14 days before planned surgery.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
- Nome: Tiffany Hodges, MD
- Número de telefone: 216-286-7122
- E-mail: tiffany.hodges@uhhospitals.org
Locais de estudo
-
-
Ohio
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals Cleveland Medical Center
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Age ≥18 years.
-
Radiographically suspected or confirmed high-grade glioma planned for surgical resection as part of standard clinical care.
-
Able to start disulfiram at least 3 days prior to planned surgery (treatment window 3-14 days pre-op).
-
In-patient status for the duration of study.
-
Karnofsky Performance Status (KPS) ≥70%.
-
Adequate organ function within 14 days prior to first dose:
- ANC ≥1.5 x 10^9/L
- Platelets ≥100 x 10^9/L
- Hemoglobin ≥9 g/dL
- AST/ALT ≤2.5 x ULN
- Total bilirubin ≤1.5 x ULN (unless Gilbert syndrome, in which case <5 x ULN).
-
Total bilirubin ≤1.5 x ULN (unless Gilbert syndrome, in which case <5 x ULN).
-
Ability to understand and willingness to sign written informed consent.
-
Willingness to avoid alcohol and alcohol-containing products during treatment and for 14 days after last dose.
Exclusion Criteria:
- Any dexamethasone (or other systemic glucocorticoid for cerebral edema) administered prior to enrollment/first dose (including outpatient or ED administration). This does not include inhalers or topical steroids.
- Imaging features that are atypical for high-grade glioma that have reasonable concern for competing differential diagnoses (e.g. PCNSL, tumefactive MS, etc.)
- Known hypersensitivity to disulfiram or thiuram derivatives.
- Active or severe hepatic disease (e.g. hepatitis, cirrhosis, known liver disease that may be exacerbated by disulfiram), or baseline liver tests above inclusion thresholds.
- Current use of metronidazole or other contraindicated interacting medications. See section 6.0; medication reconciliation for the list of medications/foods.
- Pregnant or breastfeeding. Pregnant women are excluded from the trial because the safety in pregnancy has not been established. Women who are breastfeeding are excluded from the trial because it is not known if disulfiram is present in breast milk.
- Clinically unstable neurologic status requiring immediate steroid initiation, where delaying dexamethasone for a disulfiram trial would be unsafe (investigator judgment).
- Any condition that would limit compliance with alcohol avoidance or study procedures, or that would make participation unsafe in investigator judgment.
- Subjects receiving any other investigational agents.
- Subjects with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, uncontrolled or unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição de grupo único
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Disulfiram
description here |
250 milligrams (mg) disulfiram will be given daily for 3-14 prior to operation. Participants can have the option to be treated at 500mg after initial evaluation. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Reduction in Complement Immunosuppressive program
Prazo: day 0, up to 14 days
|
Evaluate whether disulfiram given pre-operation reduces the Complement Immunosuppressive myeloid program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data. |
day 0, up to 14 days
|
|
Reduction in Scavenger Immunosuppressive program
Prazo: day 0, up to 14 days
|
Evaluate whether disulfiram given pre-operation reduces the Scavenger Immunosuppressive myeloid program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data. |
day 0, up to 14 days
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Proportion of participants needing dexamethasone within 48 hour window
Prazo: 48 hours
|
Change in investigator-rated edema symptom composite score from baseline to Day 2 on therapy. |
48 hours
|
|
Safety of disulfiram
Prazo: 14 days
|
Safety is defined as the rates of adverse events experienced by participants. Adverse event severity is graded according to the NCI Common Terminology for Adverse Events (CTCAE) Version 5.0 |
14 days
|
|
Change in Edema Symptom Composite Score (ESCS)
Prazo: day 0, up to 14 days
|
Change in ESCS is analyzed using a Wilcoxon signed-rank test |
day 0, up to 14 days
|
|
Tolerability of disulfiram
Prazo: 14 days
|
Tolerability as measured by participant toxicity rates. |
14 days
|
|
Change in Microglial Inflammatory program scores
Prazo: day 0, up to 14 days
|
Evaluate the change in microglial inflammatory program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data. |
day 0, up to 14 days
|
|
Change in Systemic Inflammatory Program Scores
Prazo: day 0, up to 14 days
|
Evaluate the change in systemic inflammatory program scores vs historical controls, which will be compared using a two-sample Wilcoxon rank-sum test (primary) and a two-sample t-test on the participant-level program scores (sensitivity). Measured using scRNA-sequence data. |
day 0, up to 14 days
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Tiffany Hodges, MD, University Hospitals Cleveland Medical Center
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CASE7326
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
De-identified individual participant data that underlie published results will be shared, as permitted by the informed consent, IRB approval, and institutional policy. This may include data dictionaries and de-identified clinical data elements needed to reproduce reported analyses, including eligibility and baseline characteristics, disulfiram exposure, dexamethasone/steroid exposure, edema-related symptom assessments, safety/adverse event data, and correlative assay-derived results from blood, tumor tissue, and CSF. Individual-level molecular, single-cell, spatial, or sequencing data will be shared only in de-identified and/or controlled-access form, as appropriate.
Prazo de Compartilhamento de IPD
Data supporting published results will be made available beginning after publication of the primary results and completion of institutional review for data release. Data will remain available for at least 3 years after publication, or longer if required by repository, journal, sponsor, or institutional policy.
Critérios de acesso de compartilhamento IPD
Access will be provided to qualified investigators for scientifically and ethically appropriate research uses, after review and approval of a written request, execution of any required data use agreement, and confirmation that the proposed use is consistent with the informed consent, IRB approval, and institutional policies. Controlled-access data will not include direct identifiers.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .